Viral RNA Testing in Hepatitis C Antibody-Positive Veterans

American Journal of Preventive Medicine

Volumn 36, Issue 3, 2009, Pages 235-238

  Rongey, Catherine A ^a,c,d   Kanwal, Fasiha ^a,e,f   Hoang, Tuyen ^c   Gifford, Allen L ^g   Asch, Steven M ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f SAINT LOUIS UNIVERSITY   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE FACTORS; AGED; CALIFORNIA; DATABASES, FACTUAL; DRUG USERS; FEMALE; GUIDELINE ADHERENCE; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; LIVER DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREJUDICE; RNA, VIRAL; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 59849120627     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2008.10.013     Document Type: Article

References (28)

1. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., and Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144 (2006) 705-714
2. Dominitz J.A., Boyko E.J., Koepsell T.D., et al. Elevated prevalence of hepatitis C infection in users of United States veterans medical centers. Hepatology 41 (2005) 88-96
3. Yee H.S., Currie S.L., Darling J.M., and Wright T.L. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol 101 (2006) 2360-2378
4. Bini E.J., Brau N., Currie S., et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 100 (2005) 1772-1779
5. Muir A.J., and Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 34 (2002) 268-271
6. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
7. Wong J.B., McQuillan G.M., McHutchison J.G., and Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90 (2000) 1562-1569
8. Hagan H., Thiede H., and Des Jarlais D.C. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 15 (2004) 543-549
9. Alter M.J., and Moyer L.A. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 18S (1998) S6-S10
10. Neri S., Bruno C.M., Abate G., et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 24 (2002) 1627-1635
11. Sylvestre D. Hepatitis C treatment in drug users: perception versus evidence. Eur J Gastroenterol Hepatol 18 (2006) 129-130
12. Hagan H., Thiede H., Weiss N.S., Hopkins S.G., Duchin J.S., and Alexander E.R. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 91 (2001) 42-46
13. Okanoue T., Makiyama A., Nakayama M., et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol 43 (2005) 599-605
14. Pradhan M.M., Horswell R., Jones G., Ramsey J.L., and Cassidy W. Evaluation of The Federal Bureau of Prisons protocol for selection of which hepatitis C-infected inmates are considered for treatment. Dig Dis Sci 50 (2005) 714-718
15. De Luca A., Di Giambenedetto S., Cingolani A., et al. Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients. AIDS 18 (2004) 1602-1604
16. Hoofnagle J.H., Di Bisceglie A.M., Waggoner J.G., and Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 104 (1993) 1116-1121
17. Crippin J.S., McCashland T., Terrault N., Sheiner P., and Charlton M.R. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 8 (2002) 350-355
18. Khaw F.M., Stobbart L., and Murtagh M.J. 'I just keep thinking I haven't got it because I'm not yellow': a qualitative study of the factors that influence the uptake of hepatitis C testing by prisoners. BMC Public Health 7 (2007) 98
19. Arora S., O'Brien C., Zeuzem S., et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol 21 (2006) 406-412
20. Wright M., Goldin R., Fabre A., et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 52 (2003) 574-579
21. Degos F., Christidis C., Ganne-Carrie N., et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 47 (2000) 131-136
22. Kermit K., Devine D.A., and Tatman S.M. High risk model of threat perception in chronic pain patients: implications for primary care and chronic pain programs. J Nerv Ment Dis 188 (2000) 577-582
23. Harris D.R., Gonin R., Alter H.J., et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 134 (2001) 120-124
24. Strader D.B., and Seeff L.B. Hepatitis C: a brief clinical overview. Ilar J 42 (2001) 107-116
25. Gaeta G.B., Stornaiuolo G., Precone D.F., et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 39 (2003) 1036-1041
26. Graham C.S., Baden L.R., Yu E., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33 (2001) 562-569
27. Stetler C.B., Mittman B.S., and Francis J. Overview of the VA Quality Enhancement Research Initiative (QUERI) and QUERI theme articles: QUERI Series. Implement Sci 3 (2008) 8
28. Wu A.H., Ghani F., Prigent F., Petry C., Armstrong G., and Graff L. Reflex testing II: evaluation of an algorithm for use of cardiac markers in the assessment of emergency department patients with chest pain. Clin Chim Acta 288 1-2 (1999) 97-109